The Effectiveness and Safety of SBRT in the Treatment of Patients With MPLC After Surgery (SMILE)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorFang Wu
About this trial
To prospectively evaluate the effectiveness and safety of SBRT in the treatment of residual malignant pulmonary nodules after lung cancer, and is committed to providing new treatment options for patients with multiple primary malignant pulmonary nodules who cannot tolerate multiple operations.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Patients with inoperable residual malignant nodules after early multiple primary lung cancer surgery
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
NO Intervention
Other interventionNO Intervention
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: SBRT group1 intervention
Trial outcomes
Primary outcomes
1
Local control rate of cancer of SBRT
Local control rate of cancer
Time frame
2-year2
Incidence of Treatment-Emergent Adverse Events of SBRT [Safety and Tolerability]
Treatment-related adverse event
Time frame
2-yearSecondary outcomes
1
Survival
Survival rate without local recurrence
Time frame
2-year2
Survival
Survival rate without distant metastasis
Time frame
2-year3
PFS
Progression-free survival rate
Time frame
2-year4
OS
Overall survival rate
Time frame
2-yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Fang Wu
Lead sponsor
Second Xiangya Hospital of Central South University
Sponsor institution
Xiangya Hospital of Central South University
Collaborator
The Third Xiangya Hospital of Central South University
Collaborator
Hunan Cancer Hospital
Collaborator
Source ClinicalTrials.gov